[Atenolol for preventing recurrence of atrioventricular reentry tachycardia in childhood].
BACKGROUND
Supraventricular reentrant tachycardias are the most common cardiac arrhythmia observed in infancy and childhood. The often benign clinical course of the disease warrants careful selection of any antiarrhythmic drug given to prevent recurrencies, in order to avoid potentially dangerous side-effects such as proarrhythmia. This study reports our experience with atenolol in the longterm treatment of infants and children with supraventricular tachycardias.


METHODS
A search of our database was made and all the children admitted in our institution between 1987 and 1995 for treatment of supraventricular tachycardia were selected. Patients who had longterm oral treatment with atenolol were retrospectively evaluated and were seen during 1996 in our outpatient clinic for a follow-up examination including a Holter-monitor.


RESULTS
14 infants and children with a median age of 2 9/12 years at first presentation could be evaluated. In 10 patients, atenolol was the first antiarrhythmic drug given. In 10 of the patients (72%) therapy with atenolol was considered successful and no further attacks of tachycardia occurred. In 2 patients a partial response to atenolol was seen with an important decrease in the frequency of tachycardias. Two patients showed no effect of treatment and the betablocker was withdrawn. The effect of the drug on heart rate and blood pressure was mild and did not lead to symptoms. In no case had the drug to be withdrawn for adverse effects. After a mean follow-up of 50 months (3-105 months), 7 patients were off the drug and free of recurrencies while among the 5 children still on atenolol, only one experienced rare episodes of tachycardia.


CONCLUSIONS
Atenolol is efficient in the longterm treatment of supraventricular tachycardias and due to its favorable risk profile can be recommended as first line treatment option.
Abteilung pädiatrische Kardiologie, Universitätskinderklinik Bern.
J P
JP
Pfammatter
J W
JW
Weber
F P
FP
Stocker
D000293:Adolescent; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001262:Atenolol / Q000008:administration & dosage* / Q000009:adverse effects; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007223:Infant; D008134:Long-Term Care; D008297:Male; D012008:Recurrence; D013611:Tachycardia, Atrioventricular Nodal Reentry / Q000188:drug therapy* / Q000209:etiology
D000889:Anti-Arrhythmia Agents; D001262:Atenolol
Atenolol zur Rezidivprophylaxe von atrioventrikulären Reentrytachykardien im Kindesalter.